Cosmo Pharmaceuticals N.V. (ETR:C43)

Cosmo Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	44.3	50.28	185.83	198.56	185.94
Short-Term Investments	17.99	-	52.7	-	-
Trading Asset Securities	80.68	-	2.43	23.65	26.92
Cash & Short-Term Investments	142.96	50.28	240.95	222.21	212.85
Cash Growth	184.36%	-79.14%	8.44%	4.40%	-20.64%
Accounts Receivable	18.94	28.45	38.61	24.45	26.99
Other Receivables	1.68	2.22	2.69	3.23	1.15
Receivables	20.62	30.67	41.3	27.68	28.14
Inventory	13.51	14.2	11.5	13.12	5.71
Prepaid Expenses	15.2	3.32	3.06	1.96	2.69
Other Current Assets	9.97	3.76	9.28	10.88	3.48
Total Current Assets	202.26	102.23	306.1	275.85	252.87
Property, Plant & Equipment	29.09	28.59	30.28	30.48	29.3
Long-Term Investments	31.84	3.29	8.27	49.08	250.61
Goodwill	24.01	24.01	24.01	24.01	1.44
Other Intangible Assets	161.66	116.15	360.89	369.31	3.24
Long-Term Deferred Tax Assets	18.72	19.83	14.68	18.64	8.2
Long-Term Deferred Charges	170.27	222.21	5.5	3.42	23.4
Other Long-Term Assets	8.94	9.75	9.87	9.78	1.81
Total Assets	646.77	526.05	759.59	805.56	596.16
Accounts Payable	9.1	8.78	7.59	8.3	5.95
Accrued Expenses	3.42	6.02	5.9	5.25	2.98
Current Portion of Long-Term Debt	0.14	0.14	171.07	0.13	0.13
Current Portion of Leases	0.68	0.76	0.76	0.76	2.81
Current Income Taxes Payable	19.95	2.17	2.29	3.25	2.46
Current Unearned Revenue	-	-	-	-	0.14
Other Current Liabilities	14.98	7.25	7.35	3.55	7.32
Total Current Liabilities	48.27	25.12	194.95	21.24	21.79
Long-Term Debt	0.28	0.42	0.56	167.15	163.02
Long-Term Leases	1.1	0.52	1.21	1.88	2.19
Long-Term Deferred Tax Liabilities	90.81	92.61	97.1	99.75	6.27
Other Long-Term Liabilities	0.57	3.2	1.58	2.39	2.39
Total Liabilities	141.68	122.42	295.8	292.88	196.04
Common Stock	4.56	4.56	4.56	4.56	3.91
Additional Paid-In Capital	243.57	243.57	243.57	243.57	84.45
Retained Earnings	373.6	271.18	310.09	341.16	265.35
Treasury Stock	-104.11	-101.31	-89.8	-65.56	-49.4
Comprehensive Income & Other	-19.28	-21.18	-11.49	-18.45	95.82
Total Common Equity	498.33	396.82	456.93	505.28	400.13
Minority Interest	6.76	6.81	6.86	7.4	-
Shareholders' Equity	505.09	403.62	463.79	512.68	400.13
Total Liabilities & Equity	646.77	526.05	759.59	805.56	596.16
Total Debt	2.2	1.84	173.6	169.92	168.14
Net Cash (Debt)	140.76	48.44	67.36	52.29	44.71
Net Cash Growth	190.61%	-28.09%	28.81%	16.96%	-56.75%
Net Cash Per Share	8.57	3.01	4.10	3.09	3.09
Filing Date Shares Outstanding	16.02	16.05	16.26	16.71	14.43
Total Common Shares Outstanding	16.02	16.05	16.26	16.71	14.43
Working Capital	153.99	77.11	111.15	254.61	231.08
Book Value Per Share	31.12	24.72	28.10	30.24	27.72
Tangible Book Value	312.67	256.66	72.04	111.96	395.44
Tangible Book Value Per Share	19.52	15.99	4.43	6.70	27.40
Land	24.64	25.01	24.97	24.02	22.79
Machinery	50.74	47.95	45.14	40.16	37.99
Construction In Progress	1.41	-	-	1.67	0.1

Updated Jul 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.